Navigation Links
Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine
Date:5/22/2013

PASADENA, Calif. May 22, 2013 The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published today in Vaccine.

The U.S. Food and Drug Administration approved PCV13 for use beginning in 2010 after a series of trials. These trials found that PCV13, which protects against a broader range of pneumococcal types than the previously used PCV7, did not increase the risk for any serious adverse events related to the vaccine.

In a study funded by the Centers for Disease Control and Prevention, Kaiser Permanente researchers evaluated the electronic medical records of nearly 600,000 children, ages 1 month to 2 years, who received PCV13 over a two-year period. Comparing the number of rare adverse events associated with the PCV13 vaccine to the number of events associated with the previously used PCV7 vaccine, the study authors found there were no increased risks for any of the following pre-specified conditions: febrile seizures, encephalopathy (a type of brain disorder), hives/angioedema, asthma, low platelet counts or systemic allergic reactions.

"It is important that children receive the pneumococcal conjugate vaccine as it provides protection against very serious and potentially fatal infections, including meningitis and bloodstream infections. The new vaccine protects against an additional six types of pneumococcal bacteria," said study lead author Hung Fu Tseng, PhD, MPH, a research scientist at the Kaiser Permanente Southern California Department of Research & Evaluation.

Early in the study, there was a statistically significant but very small increase in the risk of Kawasaki's disease, a rare condition in children that causes inflammation of the blood vessels, associated with PCV13 (7 diagnoses per 52,000 doses, compared to 4.24 expected). At the end of the study, when the diagnoses were confirmed by medical-record review, the risk of Kawasaki disease in the 28 days following PCV7 was 1 per 100,000 doses and 2 per 100,000 doses of PCV13. Although this difference was not statistically significant, the researchers note it warrants further studies. Researchers also emphasized that this is a statistical association and therefore may not represent a cause-and-effect relationship.

The CDC recommends all children ages 5 years and younger receive PCV13. The vaccine protects against pneumococcal disease, an infection caused by Streptococcus pneumoniae. The most common types of pneumococcal infections include middle-ear infections, sinus infections, lung infections, bloodstream infections and meningitis. According to the CDC, each year in the U.S. pneumococcal bacteria cause about 4,000 cases of bloodstream infections (bacteremia), meningitis, or other invasive disease in children younger than 5 years of age.

Researchers used medical records from the Vaccine Safety Datalink, a collaborative effort between the CDC and integrated care organizations, including Kaiser Permanente, to conduct the study. The Vaccine Safety Datalink project monitors immunization safety and addresses the gaps in scientific knowledge about any rare and serious events that occur following immunization.

This study is part of Kaiser Permanente's ongoing efforts to study the safety and effectiveness of vaccines. Last year, a Kaiser Permanente study conducted through the Vaccine Safety Datalink found the herpes zoster vaccine, also known as the shingles vaccine, is generally safe and well tolerated. Additionally late last year, Kaiser Permanente researchers found immunizing older adults with the tetanus-diphtheria-acellular-pertussis vaccine (Tdap) to prevent whooping cough was found to be as safe as immunizing them with the tetanus and diphtheria (Td) vaccine.


'/>"/>

Contact: Jacqueline Brown
jacqueline.brown@golinharris.com
415-318-4361
Kaiser Permanente
Source:Eurekalert

Related medicine news :

1. Antidepressants May Be Helpful for Some Heart Patients: Study
2. Study finds COPD is over-diagnosed among uninsured patients
3. Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants
4. Removing Tonsils Helps Kids With Sleep Apnea, Study Finds
5. Exposure to Secondhand Smoke May Lead to Worsening of Pediatric Kidney Disease; Pediatric Nephrology Publishes Dayton Children’s, Johns Hopkins Joint Study
6. Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer
7. Enrichment therapy effective among children with autism, UCI study finds
8. Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications
9. Bed-Sharing Raises SIDS Risk Fivefold, Study Finds
10. Certain COPD Meds Might Raise Heart Risks, Study Says
11. Sugar Injections for Knee Arthritis May Ease Pain: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... advisory organization, is proud to announce it has added CXC Solutions (CXC) as ... management solutions. These solutions are tailored to help benefits advisors reduce operating ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... portal for all the knowledge resources, including white papers, guides, handbooks, case studies, ... , To access more than 9,000 documents, webinars and videos available online, ...
(Date:12/6/2016)... ... December 06, 2016 , ... “Tatiana Sibirskaya: A Life ... story of sacrifice and enlightenment. , “Tatiana Sibirskaya: A Life Devoted ... looking for creative outlets, Carolyn gravitated toward writing through the inspiration of her ...
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates (USA) ... 125 for their industry leading training methods that engage their associates and link ... the global elite in employer-sponsored training and development programs. , “The 2017 Training ...
(Date:12/5/2016)... ... December 06, 2016 , ... For many years, Andrew G. Zubinas ... thin. The beauty of the Lithuanian language and its poetry inspired him ... book, Zubinas lyrically explores all aspects of a living, breathing forest where nothing ever ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 2016  CVS Health, the nation,s largest pharmacy innovation ... score of 100 percent on the Corporate Equality Index ... an annual national benchmarking survey and report on corporate ... the Human Rights Campaign Foundation. "Our ... colleagues, customers and suppliers bring to CVS Health," said ...
(Date:12/5/2016)... 2016  New research by the CVS Health ... the U.S. Department of Health and Human Services, ... Response (ASPR), published online today in JAMA ... encourage patients with chronic conditions to refill medications ... also affirms that public-private partnerships can facilitate timely ...
(Date:12/5/2016)... 5, 2016 For the third consecutive year, ... Human Rights Campaign Foundation,s (HRC) annual ... national benchmarking tool used to rate companies on policies ... employee equality. For the last 15 years, ... gauge their equality efforts, culture and business practices. The ...
Breaking Medicine Technology: